Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimerís disease, Parkinsonís disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha-4 integrin inhibitor primarily for the treatment of MS. It is also developing ELND005, a beta amyloid anti-aggregation agent to treat Alzheimerís disease, which completed Phase II clinical trial. In addition, the company focuses on the discovery and development of antibodies to neo-epitope related targets for the treatment of a range of indications, including amyloidosis, diabetes, cancer, and macular degeneration; and drugs for oncology related diseases comprising NEOD001 for the treatment of AL amyloidosis, as well as focuses on developing ELND005 for bipolar disorder. Further, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohnís disease. Additionally, Elan Corporation, plc, through a 49.9% interest in Janssen AI, develops beta amyloid immunotherapies, including bapineuzumab, ACC-001, and other compounds to treat Alzheimerís disease. The company also has collaboration agreements with Cambridge-Elan Centre, Dublin Neurological Institute, University College Dublin, and Proteostasis. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland.